Active — Not RecruitingNot Applicable

Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers

United Kingdom3,500 participantsStarted 2020-01-01

Plain-language summary

Urine and blood samples are being collected from patients with and without diseases of the pancreas. These samples will be tested with the aim of developing an accurate way of diagnosing diseases of the pancreas using the results.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria (Symptomatic patients): * Able and willing to give informed consent * ≥18 years old * Suspected pancreatic diseases with symptoms including, but not limited to, diarrhoea, back pain, abdominal pain, nausea, vomiting, constipation or new onset diabetes Exclusion criteria (Symptomatic patients): * Current or prior treatment (chemotherapy, radiotherapy, surgical resection, biological therapy, and immunotherapy) for any malignancy other than basal cell carcinoma within 5 years of enrolment. Asymptomatic participants will be identified through the EUROPAC registry and will fulfil EUROPAC's eligibility criteria.

What they're measuring

Accuracy of biomarker panel and affiliated risk score

Timeframe: Baseline until completion of standard-of-care diagnostic testing (up to 12 months after enrolment)

Trial details

NCT IDNCT04449406

SponsorQueen Mary University of London

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-08-31

View on ClinicalTrials.gov More Pancreatic Ductal Adenocarcinoma trials